Haibin Luo

Associate Director

Dr. Haibin Luo is an Associate Director in Biopharmaceutical Development (BPD) in AstraZeneca. He leads scientists and engineers to develop downstream manufacturing processes for inhaled biologics in AstraZeneca portfolio from early to late stage; he leads a CMC team for a new medicine targeting patients with leukemia; he also leads impurity safety risk assessment for AstraZeneca global biologics. He has 12-year experience in downstream process development for biologics like monoclonal antibody, fragmented antibodies, bispecific/tri-specific/multi-specific antibodies, and fusion proteins. He published multiple papers in downstream processing field and is an active speaker on international conferences. He did postdoc trainings at NIAID and University of Maryland before joining AstraZeneca. He received PhD degree in Drug Design from Chinese Academy of Sciences and bachelor’s degree in Biochemistry from Shandong University.

Talks About
#biopharmaceutical

Preferred Locations
#NorthAmerica